SIETES :: 93213 citas

Resultados de la búsqueda por CLORPROMACINA REFINAR BÚSQUEDA

1.

Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Rajagopalan B, On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias. A scientific statement from the American Heart Association. Circulation 2020;142:16 de septiembre. [Ref.ID 103712]

2.

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019;179:agosto. [Ref.ID 103160]

3.

Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]

4.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

5.

Park H-Y, Park J-W, Sohn HS, Kwon JW. Association of parkinsonism or Parkinson disease with polypharmacy in the year preceding diagnosis: a nested case–control study in South Korea . Drug Saf 2017;40:1109-18. [Ref.ID 102104]

6.

Anónimo. Drugs for psychotic disorders. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:160-4. [Ref.ID 101042]

7.

Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]

8.

Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]

9.

Nosè M, Recla E, Trifirò G, Barbui C. Antipsychotic drug exposure and risk pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2015;24:agosto. [Ref.ID 99472]

10.

Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. JAMA Intern Med 2015;175:408-9. [Ref.ID 98843]

11.

Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Krane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. JAMA Intern Med 2015;175:401-7. [Ref.ID 98842]

12.

Hay D, Hill M, Littlewood T. Neutropenia in primary care. BMJ 2014;349:g5340. [Ref.ID 98347]

13.

Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf 2014;37:79-90. [Ref.ID 97181]

14.

Anónimo. Atteintes de la cornée d'origine médicamenteuse. Prescrire 2013;33:908-13. [Ref.ID 96721]

15.

Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62. [Ref.ID 96106]

16.

Correli CU, De Hert M. Antipsychotics for acute schizophrenia: making choices. Lancet 2013;382:919-20. [Ref.ID 96104]

17.

Celaya Lecea MC, Martínez Basterra J. Medicamentos y prolongación del intervalo QT. Boletín de Información Farmacoterapéutica de Navarra 2013;21:1-7. [Ref.ID 95707]

18.

Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012;157:498-511. [Ref.ID 93827]

19.

Anónimo. Quetiapine (Seroquel) and QT-interval prolongation. Med Lett Drugs Ther 2011;53:79-80. [Ref.ID 91713]

20.

Anónimo. Sédation en fin de vie. En cas de détresse insupportable malgré les traitements. Prescrire 2011;31:761-6. [Ref.ID 91604]